application of high dose regimen of vancomycin in acute bacterial meningitis

Comparison of conventional vancomycin regimen (15mg/kg q12h) vs. high dose regimen (15mg/kg q8h) in acute bacterial meningitis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107233449N7

Enrollment

Registered

2011-08-08

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meningitis. Bacterial meningitis, not elsewhere classified

Interventions

Intervention 1: control group, vancomycin 1000mg q12hrs. Intervention 2: intervention group, vancomycin 1000mg q8hrs 1hr infusion.

Treatment - Drugs

control group, vancomycin 1000mg q12hrs

intervention group, vancomycin 1000mg q8hrs 1hr infusion

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Filling consent form; Patients with diagnosis of acute bacterial meningitis who are candidated for receiving vancomycin; Age=18 yrs; Not receive vancomycin in last 2weeks Exclusion criteria: Clinical states which could change phahrmacokinetic of vancomycin (eg. burn, cystic fibrosis, edema); Pregnancy; Patients with CKD who need dialysis ; Contraindication for vancomycin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum level of Cystatin-C. Timepoint: every other day. Method of measurement: mg/l.;Serum level of creatinine. Timepoint: every other day. Method of measurement: mg/dl.;Serum level of KIM-1. Timepoint: every other day. Method of measurement: pg/ml.;Serum level of vancomycin. Timepoint: third and 10th day. Method of measurement: mcg/ml.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026